The value of in vitro studies in a case of neonatal diabetes with a novel Kir6.2-W68G mutation.
Author
O'Connell, S. M.
Proks, P.
Kramer, H.
Mattis, K. K.
Sachse, G.
Joyce, C.
Houghton, J. A. L.
Ellard, Sian
Hattersley, Andrew T.
Ashcroft, F. M.
O'Riordan, S. M. P.
Date
2015-10Journal
Clinical case reportsType
Journal ArticlePublisher
WileyDOI
10.1002/ccr3.370Rights
Archived with thanks to Clinical case reportsMetadata
Show full item recordAbstract
In infants, especially with novel previously undescribed mutations of the KATP channel causing neonatal diabetes, in vitro studies can be used to both predict the response to sulphonylurea treatment and support a second trial of glibenclamide at higher than standard doses if the expected response is not observed.